Today, EU Ministers adopted a European Commission proposal to control four new psychoactive substances currently raising health concerns in Europe.
With today's decision, the substances MDPV, methoxetamine, AH-7921, and 25I-NBOMe will be subject to control measures and criminal penalties throughout the EU and their manufacturing and marketing will become illegal.
‘Continuity and change: high-risk drug use and drug treatment in Europe’, is the focus of events unfolding this week at the EMCDDA.
Newly re-elected President of the European Parliament Martin Schulz will visit the EU drugs agency (EMCDDA) and the European Maritime Safety Agency (EMSA) on 23 September, accompanied by Secretary of State for European Affairs Bruno Maçães and Mayor of Lisbon António Costa.
Leading European scientists convene in Lisbon today to undertake the risk assessment of a new psychoactive substance currently raising health concerns in Europe. The substance in question, the stimulant drug 4,4′-DMAR, is the fifth new drug to be risk assessed this year. To date, the substance has been linked to 31 deaths in the EU.
